Q1 EPS Estimate for Stoke Therapeutics Lifted by Analyst

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research report issued on Tuesday, March 18th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.57) per share for the quarter, up from their prior forecast of ($0.58). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.37) EPS, FY2026 earnings at ($3.02) EPS, FY2027 earnings at ($3.13) EPS, FY2028 earnings at ($2.69) EPS and FY2029 earnings at ($2.01) EPS.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $22.61 million for the quarter, compared to analysts’ expectations of $4.20 million.

STOK has been the topic of several other reports. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday. Chardan Capital restated a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Finally, HC Wainwright restated a “buy” rating and set a $47.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $23.00.

Stoke Therapeutics Stock Performance

STOK opened at $8.33 on Friday. Stoke Therapeutics has a 52-week low of $5.80 and a 52-week high of $17.58. The stock has a market capitalization of $441.22 million, a PE ratio of -3.97 and a beta of 0.99. The stock’s 50 day moving average price is $9.49 and its 200-day moving average price is $11.49.

Insiders Place Their Bets

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the business’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now directly owns 148,253 shares of the company’s stock, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. This represents a 5.72 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Barclays PLC raised its stake in shares of Stoke Therapeutics by 145.3% in the third quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after purchasing an additional 47,239 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Stoke Therapeutics by 9.7% in the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock worth $10,705,000 after purchasing an additional 76,661 shares during the last quarter. State Street Corp raised its stake in shares of Stoke Therapeutics by 8.6% in the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after purchasing an additional 137,145 shares during the last quarter. RTW Investments LP raised its stake in shares of Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after purchasing an additional 427,447 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of Stoke Therapeutics by 1,589.7% in the third quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock worth $936,000 after purchasing an additional 71,647 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.